Insulin resistance and obesity.

Area of Science:

• Endocrinology and Metabolism
• Molecular Biology

Background:

• Central obesity is a significant risk factor for developing insulin resistance.
• Insulin resistance is implicated in various metabolic disorders, including type 2 diabetes and polycystic ovary syndrome.
• Adipocytokines and lipid accumulation are key mechanisms linking obesity to insulin resistance.

Purpose of the Study:

• To review the mechanisms linking obesity to insulin resistance.
• To highlight the role of metformin as an insulin sensitizer.
• To discuss the significance of thiazolidinediones in understanding insulin resistance and adipocyte biology.

Main Methods:

• Literature review of studies on obesity, insulin resistance, and related metabolic conditions.
• Analysis of research on adipocytokines, lipid metabolism, and adipocyte biology.
• Examination of the therapeutic roles of metformin and thiazolidinediones.

Main Results:

• Obesity, especially central obesity, strongly correlates with insulin resistance.
• Lipid accumulation in liver and muscle, along with adipocytokines, are crucial mediators.
• Metformin's insulin-sensitizing effects are increasingly recognized.
• Thiazolidinediones represent a novel class of insulin sensitizers, advancing understanding of adipocyte biology and inflammation's role in insulin resistance.

Conclusions:

• Insulin resistance is a complex condition with multifactorial origins, strongly influenced by obesity.
• Therapeutic strategies targeting adipocyte biology and inflammation are crucial for managing insulin resistance.
• Advances in understanding insulin sensitizers like metformin and thiazolidinediones offer new avenues for treatment.